The University of Plymouth and University College London (UCL) in the UK have received a grant to support the development of a new multi-arm multi-stage (MAMS) clinical trial platform for Parkinson’s disease therapies.

The Edmond J Safra Foundation provided the £1.375m philanthropic grant to the universities.

A progressive disease, Parkinson’s causes brain degeneration that leads to tremors, stiffness and slow movements. Current therapies can relieve symptoms but do not address the disease course.

With the new platform, the universities aim to enable rapid evaluation of potential protective treatments that could slow or stop the progression of the disease in Parkinson’s patients.

The Accelerating Clinical Treatments for Parkinson’s Disease project will be named the Edmond J Safra ACT-PD Initiative. The universities will jointly lead the project, which is set to operate until 2023.

MAMS is a new trial design approach that facilitates simultaneous testing of several drugs and easy progress from early to late-stage clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Potential therapies are quickly removed and replaced at the early stage if no effectiveness is demonstrated.

The new Edmond J Safra PD MAMS Trial Platform can be used to initiate 12 drugs into a trial over five years. This process usually takes 40 years and ten times more patients compared with traditional protocols.

UCL Department of Clinical and Movement Neurosciences neurology professor Thomas Foltynie said: “Our existing process of ‘one drug at a time’ is far too inefficient, and it is high time that we had a platform capable of assessing multiple approaches simultaneously.

“This project will revolutionise the way we perform clinical trials of potentially disease-modifying drugs for people with Parkinson’s.”

The project will run in alliance with the UCL’s Medical Research Council Clinical Trials Unit, Parkinson’s researchers in the UK, Parkinson’s patients and their care partners, along with key Parkinson’s charities in the country.